Emerillon Therapeutics Inc.

Emerillon Therapeutics Inc.

December 13, 2007 08:00 ET

Emerillon Therapeutics Inc. Announces the Recruitment of Dr. Lisa Mckerracher as CEO, and Focus on Drug Development

MONTREAL, QUEBEC--(Marketwire - Dec. 13, 2007) - Emerillon Therapeutics Inc., a privately held biotechnology company, announced today the recruitment of Dr. Lisa McKerracher to lead Emerillon's management team as CEO, and a new company focus on drug development for treatment of infectious disease.

Dr. McKerracher joined Emerillon in August 2007, with a mandate to refocus Emerillon's multiple technologies towards product development and move the more advanced products into clinical trials, thus evolving Emerillon from a research stage company to a clinical stage company. According to her early evaluation, at least one compound in the infectious diseases area could enter clinical trial in the near term.

"Emerillon is an excellent opportunity because it has the essential ingredients for success: top quality science, first class drug development programs, and an experienced and tight-knit management team" said Dr. McKerracher. "Dr. Rouleau and Dr. Gros are internationally renowned scientists with a long history of creating successful drug target programs".

Dr. McKerracher has over 20 years experience in science leadership and biotechnology. As Professor at McGill University, then Universite de Montreal, she collaborated with drug companies and participated in translational science programs. She also received international recognition for her discovery of Rho as a target for regenerative medicine, namely the Christopher Reeve award which she received together with Dr. Albert Aguayo, in 2000. Dr. McKerracher was the Founding scientist and Chief Scientific Officer of BioAxone Therapeutic. She left academic research to successfully lead BioAxone's development of Cethrin®, targeting the treatment of spinal cord injury. Cethrin® was licensed to Alseres Inc. (NASDAQ:ALSE) in January 2007.

The last decade has witnessed considerable progress in elucidating the molecular mechanisms of disease, but choosing the best drug target is still very challenging. "A successful Phase III clinical program starts from a strong scientific base. It is not enough to make good drugs - the key is to home in on the right target", said Dr. McKerracher. "That is the strength of Emerillon's approach". Emerillon has two platform programs for target validation, both based on genetic approaches.

"We are pleased that Dr. McKerracher has joined the team", commented Dr. Guy Rouleau, Emerillon's President and Chief Scientific Officer. "With the invaluable experience and stellar track record of achievement of both Dr. McKerracher and Dr. Gros, our infectious disease expert, Emerillon now boasts a strong management team with all of the necessary skills to achieve its goal of becoming a highly focused clinical stage biopharmaceutical company".

About Emerillon Therapeutics Inc.

Emerillon is a Montreal-based private biotechnology firm focused on the creation of innovative drug products for the treatment of infectious disease. The company has discovered novel drug targets in infectious disease through its unique RCS mouse platform technology, and has prioritized a drug repositioning program for rapid clinical development for prevention and treatment of malaria.

Contact Information

  • Emerillon Therapeutics Inc.
    Lisa McKerracher
    Chief Executive Officer
    514-985-0306
    Info@emerillon.com